Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery.

Abstract:

:Membrane-derived vesicles (MV) are released from the surface of activated eucaryotic cells and exert pleiotropic effects on surrounding cells. Since the maintenance of pluripotency and undifferentiated propagation of embryonic stem (ES) cells in vitro requires tight cell to cell contacts and effective intercellular signaling, we hypothesize that MV derived from ES cells (ES-MV) express stem cell-specific molecules that may also support self-renewal and expansion of adult stem cells. To address this hypothesis, we employed expansion of hematopoietic progenitor cells (HPC) as a model. We found that ES-MV (10 microg/ml) isolated from murine ES cells (ES-D3) in serum-free cultures significantly (i) enhanced survival and improved expansion of murine HPC, (ii) upregulated the expression of early pluripotent (Oct-4, Nanog and Rex-1) and early hematopoietic stem cells (Scl, HoxB4 and GATA 2) markers in these cells, and (iii) induced phosphorylation of MAPK p42/44 and serine-threonine kinase AKT. Furthermore, molecular analysis revealed that ES-MV express Wnt-3 protein and are selectively highly enriched in mRNA for several pluripotent transcription factors as compared to parental ES cells. More important, this mRNA could be delivered by ES-MV to target cells and translated into the corresponding proteins. The biological effects of ES-MV were inhibited after heat inactivation or pretreatment with RNAse, indicating a major involvement of protein and mRNA components of ES-MV in the observed phenomena. We postulate that ES-MV may efficiently expand HPC by stimulating them with ES-MV expressed ligands (e.g., Wnt-3) as well as increase their pluripotency after horizontal transfer of ES-derived mRNA.

journal_name

Leukemia

journal_title

Leukemia

authors

Ratajczak J,Miekus K,Kucia M,Zhang J,Reca R,Dvorak P,Ratajczak MZ

doi

10.1038/sj.leu.2404132

subject

Has Abstract

pub_date

2006-05-01 00:00:00

pages

847-56

issue

5

eissn

0887-6924

issn

1476-5551

pii

2404132

journal_volume

20

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.

    abstract::These ECOG trials have demonstrated that progressive increments in the intensity of post-remission therapy result in improving long-term, disease-free survival in adults with AML. The median duration of disease-free survival and long-term outcome from different post-remission therapies are summarized in Table 4. [tabl...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Cassileth PA,Andersen JW,Bennett JM,Harrington DP,Hines JD,Lazarus HM,Mazza JJ,McGlave PP,O'Connell MJ,Paietta E

    更新日期:1992-01-01 00:00:00

  • FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.

    abstract::The FOXP1 (forkhead box P1) transcription factor is a marker of poor prognosis in diffuse large B-cell lymphoma (DLBCL). Here microarray analysis of FOXP1-silenced DLBCL cell lines identified differential regulation of immune response signatures and major histocompatibility complex class II (MHC II) genes as some of t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2015.299

    authors: Brown PJ,Wong KK,Felce SL,Lyne L,Spearman H,Soilleux EJ,Pedersen LM,Møller MB,Green TM,Gascoyne DM,Banham AH

    更新日期:2016-03-01 00:00:00

  • Identification of T-cell epitopes for cancer immunotherapy.

    abstract::The effectiveness of T-cell-mediated immunotherapy of cancer depends on both an optimal immunostimulatory context of the therapy and the proper selection with respect to quality and quantity of the targeted tumor-associated antigens (TAA), and, more precisely, the T-cell epitopes contained in these tumor proteins. Our...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2404787

    authors: Kessler JH,Melief CJ

    更新日期:2007-09-01 00:00:00

  • A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response.

    abstract::This phase I/II study evaluated imatinib as a c-kit inhibitor combined with mitoxantrone, etoposide and cytarabine therapy for patients with primary refractory or relapsed c-kit+ acute myeloid leukemia (AML). Imatinib was escalated through three dose levels in successive six patient cohorts. The combination was well t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.34

    authors: Brandwein JM,Hedley DW,Chow S,Schimmer AD,Yee KW,Schuh AC,Gupta V,Xu W,Kamel-Reid S,Minden MD

    更新日期:2011-06-01 00:00:00

  • The TLR1/2 agonist PAM(3)CSK(4) instructs commitment of human hematopoietic stem cells to a myeloid cell fate.

    abstract::Toll-like receptors (TLRs) constitute a family of nonpolymorphic receptors that are devoted to pathogen recognition. In this work, we have explored the impact of TLR ligands (TLR-L) on human hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). We show that HSCs and HPCs have a comparable pattern ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2009.155

    authors: De Luca K,Frances-Duvert V,Asensio MJ,Ihsani R,Debien E,Taillardet M,Verhoeyen E,Bella C,Lantheaume S,Genestier L,Defrance T

    更新日期:2009-11-01 00:00:00

  • The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation.

    abstract::Hematopoietic stem cell transplantation is becoming an increasingly important approach to treatment of different malignant and non-malignant disorders. There is thus growing demand for diagnostic assays permitting the surveillance of donor/recipient chimerism posttransplant. Current techniques are heterogeneous, rende...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.66

    authors: Lion T,Watzinger F,Preuner S,Kreyenberg H,Tilanus M,de Weger R,van Loon J,de Vries L,Cavé H,Acquaviva C,Lawler M,Crampe M,Serra A,Saglio B,Colnaghi F,Biondi A,van Dongen JJ,van der Burg M,Gonzalez M,Alcoceba M,Bar

    更新日期:2012-08-01 00:00:00

  • Clinical and cytogenetic correlations of abnormal megakaryocytopoiesis in patients with acute leukemia and chronic myelogenous leukemia in blast crisis.

    abstract::It has been suggested that abnormalities of chromosome 3 at bands q21 and q26 are associated with the presence of increased numbers of abnormal megakaryocytes in patients with hematologic malignancies. The pretreatment bone marrows of 287 patients with leukemia (acute myeloid leukemia (AML), 225 patients; acute lympho...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Lee EJ,Schiffer CA,Tomiyasu T,Testa JR

    更新日期:1990-05-01 00:00:00

  • Selected pharmacologic characteristics of idarubicin and idarubicinol.

    abstract::The pharmacology of ID and IDOL are of interest in light of the potential utility of ID in the treatment of adult and pediatric leukemia patients. Preclinical activity and cellular pharmacology of ID were suggestive of greater clinical activity when compared with several standard anthracyclines. Most intriguing were d...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Ames MM,Spreafico F

    更新日期:1992-01-01 00:00:00

  • Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells.

    abstract::Arsenic trioxide (ATO) induces disease remission in acute promyelocytic leukemia (APL) patients, but not in non-APL acute myeloid leukemia (AML) patients. ATO at therapeutic concentrations (1-2 μM) induces APL NB4, but not non-APL HL-60, cells to undergo apoptosis through the mitochondrial pathway. The role of antiapo...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.180

    authors: Wang R,Xia L,Gabrilove J,Waxman S,Jing Y

    更新日期:2013-02-01 00:00:00

  • Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

    abstract::Tyrosine kinase inhibitors have revolutionized the treatment of chronic myeloid leukemia (CML), offering patients several targeted therapeutic options that provide the possibility of sustained remissions and prolonged survival. With the availability of imatinib, nilotinib and dasatinib, physicians must weigh the effic...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2009.111

    authors: Giles FJ,O'Dwyer M,Swords R

    更新日期:2009-10-01 00:00:00

  • Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.

    abstract::We investigated the hypothesis that gemtuzumab ozogamicin (GO), an anti-CD33 immunotoxin would improve the efficacy of fludarabine/melphalan as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in a phase I/II trial. Toxicity was defined as grades III-IV organ damage, engraftment fail...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2405014

    authors: de Lima M,Champlin RE,Thall PF,Wang X,Martin TG 3rd,Cook JD,McCormick G,Qazilbash M,Kebriaei P,Couriel D,Shpall EJ,Khouri I,Anderlini P,Hosing C,Chan KW,Andersson BS,Patah PA,Caldera Z,Jabbour E,Giralt S

    更新日期:2008-02-01 00:00:00

  • Pathogenesis and prevention of HTLV-1-associated diseases.

    abstract::HTLV-1 is an important factor involved in various diseases including adult T-cell leukemia/lymphoma and HTLV-1 associated myelopathy/tropical spastic paraparesis. Amount of HTLV-1 provirus integrated in human peripheral blood mononuclear cells might be a candidate for a risk factor in the manifestation of HTLV-1 assoc...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Miwa M,Kushida S,Maeda N,Fang J,Kawamura T,Kameyama T,Uchida K

    更新日期:1997-04-01 00:00:00

  • TCR gamma/delta bearing lymphocytes in peripheral blood of allogenic bone marrow transplanted patients.

    abstract::The presence of two distinct T-cell receptors (TCR) alpha/beta and gamma/delta dimers as well as of the activated T cells was analysed in peripheral blood mononuclear cells from seventeen recipients of allogeneic bone marrow transplants for leukemia and for severe aplastic anemia. Nine of seventeen recipients expresse...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Pálóczi K,Poros A,Szelényi J,Hollán SR,Petrányi GG

    更新日期:1992-01-01 00:00:00

  • Suppression of c-myc and c-myb expression in myeloid cell lines treated with recombinant tumor necrosis factor-alpha.

    abstract::Proto-oncogenes are thought to be involved in cellular differentiation and proliferation. Tumor necrosis factors (TNFs) are specific cytokines that have cytostatic and cytotoxic effects in vitro against a wide range of human tumor cells. We have previously demonstrated that recombinant TNFs (rTNFs) have an antiprolife...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Schachner J,Blick M,Freireich E,Gutterman J,Beran M

    更新日期:1988-11-01 00:00:00

  • High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma.

    abstract::Mantle cell lymphoma (MCL) is a moderately aggressive B-cell lymphoma that responds poorly to currently used therapeutic protocols. In order to identify tumour characteristics that improve the understanding of biology of MCL, analysis of oligonucleotide microarrays were used to define specific gene expression profiles...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403057

    authors: Islam TC,Asplund AC,Lindvall JM,Nygren L,Liden J,Kimby E,Christensson B,Smith CI,Sander B

    更新日期:2003-09-01 00:00:00

  • A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.

    abstract::Retinoids have significant antiproliferative effect against chronic myelogenous leukemia (CML) cells in vitro. We conducted a pilot study to investigate the clinical effect of all-trans retinoic acid (ATRA) in patients with CML. Thirteen patients with Philadelphia chromosome (Ph)-positive CML in late chronic phase (n=...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400682

    authors: Cortes J,Kantarjian H,O'Brien S,Beran M,Estey E,Keating M,Talpaz M

    更新日期:1997-07-01 00:00:00

  • Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?

    abstract::Two proteins that have been correlated with the occurrence of multidrug resistance in acute myeloid leukemia (AML) are P-glycoprotein (Pgp) and the major vault protein (Mvp/LRP). With the purpose of further quantifying the potential contributions of Pgp-mediated drug efflux and Mvp/LRP to drug resistance in AML we hav...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401331

    authors: Broxterman HJ,Sonneveld P,Pieters R,Lankelma J,Eekman CA,Loonen AH,Schoester M,Ossenkoppele GJ,Löwenberg B,Pinedo HM,Schuurhuis GJ

    更新日期:1999-02-01 00:00:00

  • Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia.

    abstract::Acute promyelocytic leukemia (APL) is a homogeneous subgroup of acute myeloid leukemias (AML) characterized by the presence of the t(15;17) translocation and the resulting PML/RAR alpha fusion proteins. To date APL is the only AML which is sufficiently sensitive to all-trans retinoic acid (ATRA) differentiating effect...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Dubois C,Schlageter MH,de Gentile A,Balitrand N,Toubert ME,Krawice I,Fenaux P,Castaigne S,Najean Y,Degos L

    更新日期:1994-10-01 00:00:00

  • Monosomy 20 as a pointer to dicentric (9;20) in acute lymphoblastic leukemia.

    abstract::Twenty new cases of acute lymphoblastic leukemia (ALL) with the dicentric chromosome dic(9;20)(p1113;q11) are presented. This chromosomal abnormality is difficult to identify from G-banding alone. It masquerades as monosomy 20 and is only accurately identified by fluorescence in situ hybridization (FISH). Monosomy 20 ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401654

    authors: Clark R,Byatt SA,Bennett CF,Brama M,Martineau M,Moorman AV,Roberts K,Secker-Walker LM,Richards S,Eden OB,Goldstone AH,Harrison CJ

    更新日期:2000-02-01 00:00:00

  • Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL.

    abstract::Acute myelogenous leukemia (AML) remains a deadly disease for most adult patients, due primarily to the emergence of chemoresistant cells. Defects in apoptosis pathways make important contributions to chemoresistance, suggesting a need to restore apoptosis sensitivity or to identify alternative pathways for apoptosis ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403112

    authors: Suh WS,Kim YS,Schimmer AD,Kitada S,Minden M,Andreeff M,Suh N,Sporn M,Reed JC

    更新日期:2003-11-01 00:00:00

  • Translocation t(1;6)(p35.3;p25.2): a new recurrent aberration in "unmutated" B-CLL.

    abstract::Although reciprocal chromosomal translocations are not typical for B-cell chronic lymphocytic leukemia (B-CLL), we identified the novel t(1;6)(p35.3;p25.2) in eight patients with this disorder. Interestingly, all cases showed lack of somatically mutated IgV(H). Clinical, morphological, immunologic, and genetic feature...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403543

    authors: Michaux L,Wlodarska I,Rack K,Stul M,Criel A,Maerevoet M,Marichal S,Demuynck H,Mineur P,Kargar Samani K,Van Hoof A,Ferrant A,Marynen P,Hagemeijer A

    更新日期:2005-01-01 00:00:00

  • The vascular niche: home for normal and malignant hematopoietic stem cells.

    abstract::Hematopoietic stem cells (HSCs) are uniquely capable of self-renewal and provision of all of the mature elements of the blood and immune system throughout the lifetime of an individual. HSC self-renewal is regulated by both intrinsic mechanisms and extrinsic signals mediated via specialized microenvironments or 'niche...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2011.236

    authors: Doan PL,Chute JP

    更新日期:2012-01-01 00:00:00

  • Therapeutic targeting of CK2 in acute and chronic leukemias.

    abstract::CK2 is a ubiquitously expressed, constitutively active Ser/Thr protein kinase, which is considered the most pleiotropic protein kinase in the human kinome. Such a pleiotropy explains the involvement of CK2 in many cellular events. However, its predominant roles are stimulation of cell growth and prevention of apoptosi...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2017.301

    authors: Buontempo F,McCubrey JA,Orsini E,Ruzzene M,Cappellini A,Lonetti A,Evangelisti C,Chiarini F,Evangelisti C,Barata JT,Martelli AM

    更新日期:2018-01-01 00:00:00

  • A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes.

    abstract::The use of darbepoetin alfa to treat anemia in patients with lower-risk myelodysplastic syndromes (MDS) was evaluated in a phase 3 trial. Eligible patients had low/intermediate-1 risk MDS, hemoglobin ⩽10 g/dl, low transfusion burden and serum erythropoietin (EPO) ⩽500 mU/ml. Patients were randomized 2:1 to receive 24 ...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/leu.2017.192

    authors: Platzbecker U,Symeonidis A,Oliva EN,Goede JS,Delforge M,Mayer J,Slama B,Badre S,Gasal E,Mehta B,Franklin J

    更新日期:2017-09-01 00:00:00

  • Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.

    abstract::Targeted therapies are frequently combined with standard cytotoxic drugs to enhance clinical response. Targeting the B-cell lymphoma 2 (BCL-2) family of proteins is an attractive option to combat chemoresistance in leukemia. Preclinical and clinical studies indicate modest single-agent activity with selective BCL-2 in...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.243

    authors: Teh TC,Nguyen NY,Moujalled DM,Segal D,Pomilio G,Rijal S,Jabbour A,Cummins K,Lackovic K,Blombery P,Thompson E,Ekert PG,Lessene G,Glaser SP,Huang DCS,Roberts AW,Guthridge MA,Wei AH

    更新日期:2018-02-01 00:00:00

  • DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells.

    abstract::The FMS-like tyrosine kinase-3 (FLT3) gene is the most commonly mutated gene in acute myeloid leukemia (AML), and patients carrying internal tandem duplication (ITD) mutations have a poor prognosis. Long-term inhibition of FLT3 activity in these patients has been elusive. To provide a more complete understanding of FL...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.284

    authors: Wu M,Hamaker M,Li L,Small D,Duffield AS

    更新日期:2017-03-01 00:00:00

  • In vitro effects of IL-2 on NK-activity, clonogenic potential, blast cell proliferation and cytokine release of MDS bone marrow patients.

    abstract::To evaluate the clinical usefulness of IL-2 in myelodysplastic syndromes (MDS) the in vitro effects of interleukin-2 (IL-2) on blast cell proliferation, clonogenic activity, cytokine release and cell mediated cytotoxicity were examined in 49 MDS patients. Morphological analyses of bone marrow (BM) cytospin preparation...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Cortelezzi A,Sarina B,Cattaneo C,Pomati M,Silvestris I,Soligo D,Calori R,Di Stefano M,Hu C,Monza M,Radelli L,Maiolo AT

    更新日期:1996-07-01 00:00:00

  • Nine years' experience with ABMT in 128 patients with Hodgkin's disease: an Italian study group report.

    abstract::One-hundred, twenty-eight patients with Hodgkin's disease in remission or who had failed a mechlorethamine, vincristine, procarbazine and prednisone (MOPP), a doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) and/or lomustine, etoposide and prednimustine (CEP) regimens have been treated with a high-dose thera...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Carella Am,Carlier P,Congiu A,Occhini D,Meloni G,Anselmo AP,Mandelli F,Mazza P,Tura S,Mangoni L

    更新日期:1991-01-01 00:00:00

  • Dissecting the pathways to death.

    abstract::This report summarizes recent findings in the field of basic and translational apoptosis research which were presented at the 1st Conference on 'Mechanisms of Cell Death and Disease: Advances in Therapeutic Intervention' organized by the European School of Hematology and the University of Texas MD Anderson Cancer Cent...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2401940

    authors: Daniel PT

    更新日期:2000-12-01 00:00:00

  • Clonal instability preceding lymphoid blastic transformation of chronic myeloid leukemia.

    abstract::We have sought the presence of rearrangements of the immunoglobulin heavy chain gene locus in 13 patients with chronic myeloid leukemia (CML) in lymphoid blastic transformation (L-BT) using the polymerase chain reaction (PCR). The lymphoid nature of the transformation was confirmed by immunophenotyping and/or Southern...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400543

    authors: Spencer A,Vulliamy T,Kaeda J,Goldman JM,Melo JV

    更新日期:1997-02-01 00:00:00